Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, CRISPR Therapeutics AG’s stock clocked out at $42.82, up 1.66% from its previous closing price of $42.12. In other words, the price has increased by $1.66 from its previous closing price. On the day, 1.13 million shares were traded. CRSP stock price reached its highest trading level at $43.32 during the session, while it also had its lowest trading level at $41.455.
Ratios:
To gain a deeper understanding of CRSP’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.07 and its Current Ratio is at 22.07. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Evercore ISI on February 14, 2025, Upgraded its rating to Outperform and sets its target price to $99 from $60 previously.
On February 12, 2025, TD Cowen Upgraded its rating to Hold which previously was Sell but kept the price unchanged to $35.
On February 03, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $65.H.C. Wainwright initiated its Buy rating on February 03, 2025, with a $65 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 11 ’25 when Kulkarni Samarth sold 9,973 shares for $42.42 per share. The transaction valued at 423,055 led to the insider holds 180,890 shares of the business.
Kulkarni Samarth sold 4,462 shares of CRSP for $193,294 on Mar 12 ’25. The Chief Executive Officer now owns 185,428 shares after completing the transaction at $43.32 per share. On Mar 11 ’25, another insider, KASINGER JAMES R., who serves as the General Counsel and Secretary of the company, sold 2,850 shares for $42.42 each. As a result, the insider received 120,897 and left with 77,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 3672864000 and an Enterprise Value of 1992729984. For the stock, the TTM Price-to-Sale (P/S) ratio is 98.44 while its Price-to-Book (P/B) ratio in mrq is 1.90. Its current Enterprise Value per Revenue stands at 53.404 whereas that against EBITDA is -4.455.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.76, which has changed by -0.40494722 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $75.91, while it has fallen to a 52-week low of $36.52. The 50-Day Moving Average of the stock is -0.25%, while the 200-Day Moving Average is calculated to be -11.75%.
Shares Statistics:
It appears that CRSP traded 2.14M shares on average per day over the past three months and 1652690 shares per day over the past ten days. A total of 85.74M shares are outstanding, with a floating share count of 82.09M. Insiders hold about 4.30% of the company’s shares, while institutions hold 69.38% stake in the company. Shares short for CRSP as of 1740700800 were 20808121 with a Short Ratio of 9.70, compared to 1738281600 on 19491883. Therefore, it implies a Short% of Shares Outstanding of 20808121 and a Short% of Float of 27.48.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
